REPORTING OF CARDIOVASCULAR RISK FACTORS IN LANDMARK IMMUNE CHECKPOINT INHIBITOR TRIALS

被引：0
|
作者：
Tan, Sean
Sivakumar, Seiyon
Segelov, Eva
Nicholls, Stephen J.
Nelson, Adam J.
机构：
[1] Victorian Heart Inst, Melbourne, Vic, Australia
[2] Monash Heart, Melbourne, Vic, Australia
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1154-007
引用
收藏
页码：2168 / 2168
页数：1
相关论文
共 50 条
  • [1] Cardiovascular risk factor reporting in immune checkpoint inhibitor trials: A systematic review
    Tan, Sean
    Sivakumar, Seiyon
    Segelov, Eva
    Nicholls, Stephen J.
    Nelson, J.
    CANCER EPIDEMIOLOGY, 2023, 83
  • [2] Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
    Laura I. Yousif
    Elles M. Screever
    Daniëlle Versluis
    Joseph Pierre Aboumsallem
    Stefan Nierkens
    Olivier C. Manintveld
    Rudolf A. de Boer
    Wouter C. Meijers
    Current Oncology Reports, 2023, 25 : 753 - 763
  • [3] Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities
    Yousif, Laura I.
    Screever, Elles M.
    Versluis, Danielle
    Aboumsallem, Joseph Pierre
    Nierkens, Stefan
    Manintveld, Olivier C.
    de Boer, Rudolf A.
    Meijers, Wouter C.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (07) : 753 - 763
  • [4] Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials
    Rankin, Stephen
    Elyan, Benjamin
    Jones, Robert
    Venugopal, Balaji
    Mark, Patrick B.
    Lees, Jennifer S.
    Petrie, Mark C.
    Lang, Ninian N.
    JACC: CARDIOONCOLOGY, 2024, 6 (02): : 267 - 279
  • [5] Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
    Chen, Chen
    Zhou, Yixin
    Zhang, Xuanye
    Wang, Yuhong
    He, Li-na
    Lin, Zuan
    Chen, Tao
    Jiang, Yongluo
    Hong, Shaodong
    Zhang, Li
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [6] Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
    Flora Pirozzi
    Remo Poto
    Luisa Aran
    Alessandra Cuomo
    Maria Rosaria Galdiero
    Giuseppe Spadaro
    Pasquale Abete
    Domenico Bonaduce
    Gianni Marone
    Carlo Gabriele Tocchetti
    Gilda Varricchi
    Valentina Mercurio
    Current Oncology Reports, 2021, 23
  • [7] Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
    Pirozzi, Flora
    Poto, Remo
    Aran, Luisa
    Cuomo, Alessandra
    Galdiero, Maria Rosaria
    Spadaro, Giuseppe
    Abete, Pasquale
    Bonaduce, Domenico
    Marone, Gianni
    Tocchetti, Carlo Gabriele
    Varricchi, Gilda
    Mercurio, Valentina
    CURRENT ONCOLOGY REPORTS, 2021, 23 (02)
  • [8] Reporting of immune checkpoint inhibitor-associated myocarditis
    Al-Kindi, Sadeer G.
    Oliveira, Guilherme H.
    LANCET, 2018, 392 (10145): : 382 - 383
  • [9] Risk Factors for Immune Checkpoint Inhibitor-Induced Diabetes Identified
    Anderer, Samantha
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (15):
  • [10] Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes
    Derry-Vick, Heather
    Zaemes, Jacob Peter
    Ahn, Jaeil
    Pascual, Lauren
    Sinclaire, Brittany
    Lev-Ari, Shaked
    Alaoui, Adil
    Sridhar, Aishwarya
    Adams, David
    Della Pia, Alexandra
    Pecora, Andrew L.
    Atkins, Michael B.
    Ip, Andrew
    Shah, Neil J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345